JMP Securities analyst Liisa Bayko reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) on September 20 and set a price target of $27. The company’s shares closed on Friday at $6.95.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 23.9% and a 53.2% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $29.33, which is a 322.0% upside from current levels. In a report issued on September 13, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.96 and a one-year low of $4.50. Currently, Corbus Pharmaceuticals has an average volume of 818.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
